复合三联抗结核药人工缓释材料体外抗结核性能  

Vitro anti-tuberculosis performance of artificial release material compounded triple anti-tuberculosis

作　　者：张峻山[1] 王自立[2] 施建党[2] 刘海涛[2] 肖慧霞 牛宁奎[2] 

机构地区：[1]潍坊市人民医院脊柱骨科,山东261041 [2]宁夏医科大学总医院骨科 [3]宁夏第四人民医院骨科

出　　处：《脊柱外科杂志》2014年第6期380-384,共5页Journal of Spinal Surgery

基　　金：国家自然科学基金(81060149);宁夏自然科学基金(NZ10117)

摘　　要：目的评价复合三联抗结核药硫酸钙/聚氨基酸人工缓释材料的体外抗结核性能。方法将制作的载药人工缓释材料及非载药缓释材料浸泡于模拟体液中,分别于第4周、第8周、第12周取得二者的浸提液,采用高效液相色谱法检测浸提液浓度。实验分为3组:实验组(A组)为复合三联抗结核药人工缓释材料第4、8、12周的浸提液组,分为A4W、A8W、A12W3个亚组;实验对照组(B组)为未载药人工缓释材料第4、8、12周的浸提液组,分为B4W、B8W、B12W3个亚组;空白对照组(C组)为蒸馏水,分为C4W、C8W、C12W3个亚组,每个亚组均为20个样本。将进行增殖后的标准结核分枝杆菌H37Rv与3组各样本加入Bac T/ALERT 3D培养系统中共同培养。观察阳性率并统计分析培养结果。结果复合三联抗结核药硫酸钙/聚氨基酸人工缓释材料浸提液浓度检测结果(μg/m L):第4、8、12周时异烟肼的浓度分别为:142.65±2.23,47.83±2.91,0.68±0.17;利福平在第4、8周时的浓度分别为:70.69±7.16,39.95±3.98,第12周时其浓度已测不到;吡嗪酰胺在第4、8、12周时的浓度分别为:893.56±7.09;229.87±9.56,6.36±0.57。经Bac T/ALERT 3D系统培养后,A、B、C各亚组结核杆菌阳性率分别为:A4W组15%、A8W组25%、A12W组55%;B4W组80%、B8W组85%、B12W组80%;C4W组90%、C8W组95%、C12W组90%。A组各样本与B组对应样本比较差异有统计学意义(P<0.05)。B组各样本与C组之间比较差异无统计学意义(P>0.05)。结论本研究表明复合三联抗结核药硫酸钙/聚氨基酸人工缓释材料在体外具有抗结核作用,其作用至第84天仍然存在。Objective To evaluate vitro anti-tuberculosis performance of calcium sulfate/poly amino acids artificial release material compounded triple anti-tuberculosis drugs Methods Soak the calcium sulfate/poly amino acids artificial release ma-terial compounded triple anti-tuberculosis drugs and the calcium sulfate/poly amino acids artificial release material uncom-pounded triple anti-tuberculosis drugs in the simulation of body fluid.Detect the concentration of extracts obtained in 4th week, 8th week, 12th week with high performance liquid chromatography （HPLC）.Experimental group（Group A） was the extracts of calcium sulfate/poly amino acids artificial release material compounded triple anti-tuberculosis drugs in 4th week, 8th week and 12th week, divided into A4W, A8W, A12W 3 sub-groups;experimental control group （Group B） was the extracts of calcium sulfate/poly amino acids artificial release material uncompounded triple anti-tuberculosis drugs in 4th week, 8th week and 12th week, divided into B4W, B8W, B12W 3 sub-groups; blank control group（Group C） was distilled water group, divided into C4W , C8W , C12W 3 sub-groups, each sub-group of 20 samples.Three groups of samples and standard tuberculosis H37Rv were added into BacT/ALERT 3D co-culture fast training instrument,then observe the positive rate of culture results and did statistical analysis .Results The result of the extracts concentration of the calcium sulfate /poly amino acids artificial release material compounded triple anti-tuberculosis drugs （μg/mL）：the concentration of isonicotinyl hydrazide in 4th week, 8thweekand12thweekwas142.65 ±2.23,47.83 ±2.91,0.68 ±0.17,respectively.Theconcentrationofrifampinin4th week, 8th week was 70.69 ±7.16, 39.95 ±3.98, respectively, the concentration could not be detected in 12th week.The concentration of pyrazinamide in 4 th week , 8 th week and 1 2 th week was 8 9 3 .5 6 ±7 .0 9 , 2 2 9 .8 7 ±9 .5 6 , 6 .3 6 ±0 .5 7 ,＆amp;nbsp;respectively.After co-cultured in BacT/ALERT 3D system, the positiv

关 键 词：结核 脊柱 药物疗法 联合 缓效制剂 药物评价 

分 类 号：R529.2[医药卫生—内科学]